MedTrace Logo

the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

NCT05851105 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-11-29

No results posted yet for this study

Summary

This is an open label study to evaluate the safety and efficacy of α-globin Restored Autologous Hematopoietic Stem Cells in α-Thalassemia Major Patients

Conditions

  • α-thalassemia

Interventions

BIOLOGICAL

α-globin restored autologous hematopoietic stem cells

α-globin restored autologous hematopoietic stem cells modified with LentiHBA T\>C

Sponsors & Collaborators

  • Shenzhen Hemogen

    lead INDUSTRY

Principal Investigators

  • Chao Liu, PHD · Shenzhen Hemogen

  • Xinhua Zhang · PLA Joint Logistic Support Force No. 923 Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-08
Primary Completion
2026-12-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05851105 on ClinicalTrials.gov